Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 1 · 50%Moderate 0 · 0%High 0 · 0%

Infliximab 5–10 mg/kg vs placebo

Induction of 70‐point clinical response CDAI · Patients with active Crohn's disease

Infliximab 5–10 mg/kg may leads to higher clinical response defined as improvement in the scores on the CDAI… compared with placebo (low certainty).

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 4.09 [1.63, 10.25]
1 study · 80 participants
Low

Infliximab 5–10 mg/kg vs placebo

Clinical response defined as reduction of 50% in the number of draining fistula at ≥ 2 consecutive visits, at a median length of time of 12 weeks · Patients with active Crohn's disease

It is very uncertain whether infliximab 5–10 mg/kg changes clinical response defined as reduction of 50% in the number of… compared with placebo (very low certainty).

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 1.94 [1.1, 3.41]
2 studies · 181 participants
Very low